Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of introducing a policy of pre-exposure protection using new and emerging monoclonal antibody and antiviral treatments for immunosuppressed people who remain vulnerable to covid-19 despite receiving a vaccination.

Immunocompromised individuals are a priority cohort for research into therapeutic and prophylaxis treatments, such as monoclonal antibody therapies and repurposed compounds.  The RAPID C-19 collaboration has enabled active multi-agency oversight of national and international trial evidence as it emerges for COVID-19 therapies, both in potential treatment and prophylactic indications. Where material evidence is identified, this has enabled the rapid formation and implementation of United Kingdom-wide clinical access policies. The RAPID C-19 collaboration actively reviews all promising compounds. To date, the evidence has most strongly supported treatment use, but the evidence around prophylactic use will continue to be actively reviewed.